Skip to main content
. 2021 Aug 12;9(8):894. doi: 10.3390/vaccines9080894

Figure 2.

Figure 2

Overall survival relationship of Vigil treatment recurrent/refractory ovarian cancer patients by γ-IFN-ELISPOT-positive vs. γ-IFN-ELISPOT-negative recurrent ovarian cancer patients from time of tissue procurement (A) and start of treatment (B).